Joshua Richter
Overview
Explore the profile of Joshua Richter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
1205
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Avigan Z, Rattu M, Richter J
Expert Opin Biol Ther
. 2025 Feb;
25(3):221-228.
PMID: 39923122
Introduction: Bispecific antibody therapies, primarily targeting B-cell maturation antigen (BCMA), have shown remarkable outcomes in the treatment of heavily pretreated patients with multiple myeloma (MM). However, there are no current...
2.
Wattana M, Rowland J, Qdaisat A, Levavi H, Anagnostou T, Sanchez L, et al.
Cancer Treat Rev
. 2025 Feb;
134:102889.
PMID: 39913958
Background: T-cell-engaging bispecific antibodies (BsAbs) are a newer type of immunotherapy designed to boost T-cell cytotoxicity. They are increasingly used in cancer treatment, with drugs currently being tested and authorized...
3.
Richter J, Dhodapkar M, Li M, Awad M, Hampp C, Knorr K, et al.
Am J Hematol
. 2025 Jan;
100(4):548-551.
PMID: 39887567
No abstract available.
4.
Mouhieddine T, Costa B, Richter J
Semin Hematol
. 2025 Jan;
PMID: 39880754
Recent advancements in multiple myeloma (MM) treatment-including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and T cell-redirecting therapies like chimeric antigen receptor (CAR) T cells and bispecific antibodies (BsAbs)-have significantly improved...
5.
Costa L, Banerjee R, Mian H, Weisel K, Bal S, Derman B, et al.
Leukemia
. 2025 Jan;
39(3):543-554.
PMID: 39870767
T-cell redirecting therapy (TCRT), specifically chimeric antigen receptor T-cell therapy (CAR T-cells) and bispecific T-cell engagers (TCEs) represent a remarkable advance in the treatment of multiple myeloma (MM). There are...
6.
Chen L, Thibaud S, Bodnar S, Chari A, Richter J, Cho H, et al.
Blood Adv
. 2024 Nov;
9(1):176-179.
PMID: 39546749
No abstract available.
7.
Avigan Z, Arinsburg S, Pan D, Mark T, Fausel C, Bubalo J, et al.
Bone Marrow Transplant
. 2024 Oct;
60(1):115.
PMID: 39424960
No abstract available.
8.
Costa B, Costa T, Cavalcante Lima Chagas G, Mouhieddine T, Richter J, Usmani S, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Oct;
25(1):32-44.
PMID: 39414558
Background: The efficacy of elotuzumab, an anti-SLAMF7 monoclonal antibody, in treating relapsed/refractory multiple myeloma (RRMM) and newly-diagnosed multiple myeloma (NDMM) has varied in randomized controlled trials (RCTs). Moreover, there is...
9.
Avigan Z, Bodnar S, Pan D, Catlett J, Richter J, Sanchez L, et al.
Blood Adv
. 2024 Oct;
9(1):202-206.
PMID: 39383457
No abstract available.
10.
Thibaud S, Subaran R, Newman S, Lagana A, Melnekoff D, Bodnar S, et al.
Blood Cancer Discov
. 2024 Sep;
5(6):428-441.
PMID: 39283238
First-degree relatives of patients with multiple myeloma are at increased risk for the disease, but the contribution of pathogenic germline variants (PGV) in hereditary cancer genes to multiple myeloma risk...